Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells

NeuroReport

Volumn 21, Issue 9, 2010, Pages 629-635

  Wang, Shouli ^a   Yan, Chenghui ^a   Xu, Hui ^b   Zhao, Xin ^a   Han, Yaling ^a  

^a Shenyang Northern Hospital   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cilostazol; Experimental autoimmune encephalomyelitis; Phosphodiesterase inhibitor; T cell

Indexed keywords

ANTIGEN; CILOSTAZOL; GAMMA INTERFERON; INTERLEUKIN 17; MITOGENIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; TETRAZOLE DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TETRAZOLES; TH1 CELLS; TREATMENT OUTCOME; PHOSPHODIESTERASE 3 INHIBITORS;

EID: 77953536348     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32833a4d4d     Document Type: Article

References (18)

1. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678-686.
2. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100:1261-1275.
3. Lim JH, Woo JS, Shin YW. Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38MAPKdependent pathways. Korean J Intern Med 2009; 24:113-122.
4. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, et al. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000; 108:136-146.
5. Xu H, Strassmann G, Chan CC, Rizzo LV, Silver PB, Wiggert B, et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest Ophthalmol Vis Sci 1999; 40:942-950.
6. Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, et al. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem 2008; 103:54-66.
7. Kureshiro J, Miyamoto K, Tanaka N, Kusunoki S. Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis. Neuroreport 2009; 20:718-722.
8. Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 2007; 7:904-912.
9. Zhang GX, Yu S, Gran B, Li J, Siglienti I, Chen X, et al. Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis. J Immunol 2003; 171:4485-4492.
10. Shevach EM, Chang JT, Segal BM. The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. Springer Semin Immunopathol 1999; 21:249-262.
11. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008; 57:115-120.
12. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; 179:3268-3275.
13. Mekala DJ, Geiger TL. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 2005; 105:2090-2092.
14. Martinez I, Puerta C, Redondo C, Garcia-Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. J Neurol Sci 1999; 164:13-23.
15. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007; 8:1372-1379.
16. Agrawal NK, Maiti R, Dash D, Pandey BL. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res 2007; 56:118-123.
17. Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, et al. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther 2009; 329:571-579.
18. Yoshida N, Shimizu Y, Kitaichi K, Hiramatsu K, Takeuchi M, Ito Y, et al. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin Exp Immunol 2001; 126:384-389.